Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...

Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia ...

While gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of pipeline and marketed gMG drugs.

AZ has already made it clear its focus is on investing in the US market – which accounts for 30% of its sales – and started ...

PREVAIL phase III trial of gefurulimab meets its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in MG-ADL ...

(Alliance News) - AstraZeneca PLC on Thursday said phase 3 data regarding its investigational inhibitor gefurulimab met its primary endpoint in myasthenia gravis activities of daily living.

Results from the global PREVAIL Phase 3 trial showed that gefurulimab met its primary endpoint, demonstrating a statistically significant and ...

Despite growing competition and an expanding array of differentiated dosing profiles designed to enhance patient convenience, retention on first-line biologics remains exceptionally high at 90%, ...

Oral therapy showed dose-dependent increases in progranulin protein levels in both plasma and cerebrospinal fluid; >95% mean increase in progranulin levels in CSF, compared to baseline; favorable ...

Here are the top FTSE 100 Index shares to watch next week, including BT Group, BP, IAG, Marks and Spencer (MKS) and AstraZeneca ...

(Sharecast News) - AstraZeneca has struck a deal with the White House to cut drugs prices in America, allowing it to avoid steep tariffs on US imports. In a statement released on Monday, the ...

The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with alternatives from Roche and AstraZeneca.